- Supported exchanges /
- F /
- E4NA.F
AROVELLA THERAPEUTICS (E4NA F) stock market data APIs
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
AROVELLA THERAPEUTICS Financial Data Overview
| 0.113 | |
| 0.113 | |
| - | |
| 0.113 | |
| 0.113 | |
| 0.04-0.116 | |
| 120 M | |
| 1 052 M | |
| 1 952 K | |
| -0.042 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
AROVELLA THERAPEUTICS Fundamental Data is available in our Financial Data APIs
- Net Revenue 1 952 K
- EBITDA -8 833 160
- Earnings Per Share -0.01
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get AROVELLA THERAPEUTICS Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get AROVELLA THERAPEUTICS End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
